Xinchun Tong - Concepedia

Author

Xinchun Tong

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Tong, Xinchun, X TONG, X Tong, X. S. Tong, X. Tong, Xin-Chun Tong, Xinchun S Tong, Xinchun S. Tong, Xinchun Tong, Xinchun. Tong

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy

About

Xinchun Tong is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	61	2.4K
2	Natural Sciences	15	20	806
3	Engineering	5	5	281
4	Social Sciences	2	2	205
5	Health Sciences	1	1	71

Xinchun Tong

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034 Xinchun Tong, Robert A. Chase, Angela Skelton, Antiviral Research Drug Resistance AnalysisMolecular VirologyGeneticsMolecular BiologyVirology	2006	233
Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia Yin Wu, Ester Carballo‐Jane, David G. McLaren, Journal of Lipid Research	2011	210
Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice Lauren P. Shearman, Kim Rosko, R. Fleischer, Behavioural Pharmacology Anorectic EffectsFood IntakePsychopharmacologyCannabinoid PharmacologySocial Sciences	2003	186
Chiral Separation and Detection of Terbutaline and Ephedrine by Capillary Electrophoresis Coupled with Ion Spray Mass Spectrometry Robin L. Sheppard, Xinchun Tong, Jianyi Cai, Analytical Chemistry EngineeringOrganic ChemistryIon MonitoringMedicinal ChemistrySeparation Science	1995	133
Characterization of resistance mutations against HCV ketoamide protease inhibitors Xinchun Tong, Stéphane Bogen, Robert A. Chase, Antiviral Research Drug DiscoveryResistance Mutation (Virology)Resistance MutationsBiomolecular EngineeringDrug Resistance	2008	127
Discovery of <i>N</i>-[(1<i>S</i>,2<i>S</i>)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity Linus S. Lin, Thomas J. Lanza, James P. Jewell, Journal of Medicinal Chemistry Cannabis UseMolecular PharmacologyMedicinal ChemistryCompound 48Biochemistry	2006	122
Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1 S,2 S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents Tung M. Fong, Xiao-Ming Guan, Donald J. Marsh, Journal of Pharmacology and Experimental Therapeutics	2007	100
Discovery of a Novel Glucagon Receptor Antagonist<i>N</i>-[(4-{(1<i>S</i>)-1-[3-(3, 5-Dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1<i>H</i>-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the Treatment of Type II Diabetes Yusheng Xiong, Jian Guo, Mari R. Candelore, Journal of Medicinal Chemistry	2012	86
Correolide and Derivatives Are Novel Immunosuppressants Blocking the Lymphocyte Kv1.3 Potassium Channels Gloria C. Koo, Joseph T. Blake, Kashmira Shah, Cellular Immunology InflammationMolecular PhysiologyHyperpolarization (Biology)MedicineImmunosuppressive Therapy	1999	81
Discovery of Novel Tricyclic Full Agonists for the G-Protein-Coupled Niacin Receptor 109A with Minimized Flushing in Rats Hong C. Shen, Fa‐Xiang Ding, Qiaolin Deng, Journal of Medicinal Chemistry Tricyclic AnaloguesMedicinal ChemistryBiochemistryFunctional SelectivityMedicine	2009	78

Page 1